MASTER DEVELOPMENT AND MANUFACTURING AGREEMENTMaster Development and Manufacturing Agreement • June 18th, 2018 • Magenta Therapeutics, Inc. • Pharmaceutical preparations • New York
Contract Type FiledJune 18th, 2018 Company Industry JurisdictionThis Master Development and Manufacturing Agreement (including all appendices hereto, this “Agreement”) is entered into as of February 13, 2018 (the “Effective Date”) by and between Magenta Therapeutics, Inc., a Delaware corporation having offices at 50 Hampshire Street, 8th Floor, Cambridge, MA 02139 (“Magenta”), and Bachem Americas, Inc., a California corporation, having offices at 3132 Kashiwa Street, Torrance, CA 90505 (“Bachem”). Magenta and Bachem may be referred to individually as a “Party” or collectively as the “Parties.”
MASTER DEVELOPMENT AND MANUFACTURING AGREEMENT by and between PUREPAC PHARMACEUTICAL CO. and SHASUN CHEMICALS AND DRUGS LIMITED Dated as of May 27th, 2005Master Development and Manufacturing Agreement • August 2nd, 2005 • Alpharma Inc • Pharmaceutical preparations • New York
Contract Type FiledAugust 2nd, 2005 Company Industry JurisdictionThis MASTER DEVELOPMENT AND MANUFACTURING AGREEMENT (the "Agreement") is made as of May 27th, 2005, (the "Effective Date") by and between Purepac Pharmaceutical Co., organized and existing under the laws of the State of Delaware, USA, and its affiliates and related companies, all Alpharma corporations (referred to herein as "Alpharma") and Shasun Chemicals and Drugs Limited, a company organized under the laws of India (referred to herein as "Shasun" or "Manufacturer") (Alpharma and Shasun each a party and together are the "parties").
MASTER DEVELOPMENT AND MANUFACTURING AGREEMENT Clinical ProductsMaster Development and Manufacturing Agreement • August 14th, 2007 • Aradigm Corp • Electromedical & electrotherapeutic apparatus • New Jersey
Contract Type FiledAugust 14th, 2007 Company Industry JurisdictionThis Master Development and Manufacturing Agreement (this “Agreement”) is entered into as of August 8, 2007, (the “Effective Date”) by and between Enzon Pharmaceuticals, Inc., a Delaware corporation with an address of 685 Route 202-206, Bridgewater, New Jersey 08807 (“Enzon”), and Aradigm Corporation, a California corporation, having its principal place of business at 3929 Point Eden Way, Hayward, CA 94545 (“Aradigm”). Enzon and Aradigm may be referred to individually as a “Party” or collectively as “Parties.”